Communiqués Scinai Immunotherapeutics Ltd.

Actions

SCNI

US09073Q3039

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 17:36:56 30/07/2026			Varia. 5j.	Varia. 1 janv.
0,2506 ^USD	-6,04 %		+1,42 %	-64,81 %

15/06	Scinai Immunotherapeutics Ltd. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/05	Scinai Immunotherapeutics Ltd. nomme Eilon Elmalem au poste de directeur du site CDMO de Yavne, avec effet au 14 juin 2026	CI

Communiqués

18/05	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe	AQ
27/04	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing	AQ
19/03	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026	PR
16/03	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price	PR
02/03	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept	PR
07/01	Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL	PR
02/12	Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances	PR
06/10/25	Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities	PR
02/09/25	Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet	PR
29/07/25	Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN	PR
07/05/25	Scinai Announces Annual Financial Results for 2024	PR
07/01/25	Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences	AQ
28/11/24	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics Scientific Advisory Board	AQ
25/11/24	Scinai Immunotherapeutics : Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million Form 6 K	PU
22/11/24	Scinai Immunotherapeutics : Report Of Foreign Private Issuer Form 6 K	PU
22/11/24	Scinai Immunotherapeutics : Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million	PU
01/11/24	Scinai Immunotherapeutics Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024	AQ
15/10/24	Scinai Immunotherapeutics : Jerusalem BioPark, 2nd FloorHadassah Ein Kerem CampusJerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERSTo Be Held on November 21, 2024 Form 6 K	PU
09/09/24	IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.	AQ
30/08/24	Scinai Immunotherapeutics Regains Full Compliance with Nasdaq Listing Requirements	AQ
14/08/24	Scinai Announces Signing of Loan Restructuring Agreement withEuropean Investment Bank, Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity	AQ
05/08/24	Scinai Immunotherapeutics : NOTICE TO SHAREHOLDERS RE. SUPPLEMENTAL CHANGES TO PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING Form 6 K	PU
16/07/24	SCINAI IMMUNOTHERAPEUTICS ANNOUNCES PROMISING RESULTS IN AN IN-VIVO PROOF-OF-CONCEPT PSORIATIC HUMAN SKIN MODEL	AQ
09/07/24	SCINAI IMMUNOTHERAPEUTICS ANNOUNCES RECEIPT OF AN UPDATED LETTER OF INTENT FROM THE EUROPEAN INVESTMENT BANK PROVIDING SPECIFIC TERMS FOR CONVERSION OF ITS LOAN TO EQUITY	AQ
04/07/24	SCINAI IMMUNOTHERAPEUTICS GRANTED EXTENSION BY NASDAQ HEARING PANEL TO REGAIN COMPLIANCE WITH CONTINUED LISTING REQUIREMENTS	AQ